OTC:AVCNF - Avicanna Stock Price Target and Predictions

  • Consensus Rating: Sell
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 1
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.31
▲ +0.0327 (11.60%)

This chart shows the closing price for AVCNF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Avicanna Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AVCNF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AVCNF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Avicanna in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a -100.00% upside from the last price of $0.31.

This chart shows the closing price for AVCNF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Sell

The current consensus among 1 contributing investment analysts is to sell stock in Avicanna.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/4/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/2/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/31/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
11/29/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
2/27/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
4/28/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
5/28/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/15/2021Raymond JamesDowngradeOutperform ➝ Underperform
(Data available from 5/28/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/29/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/29/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/28/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/27/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/29/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/28/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/28/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.

Avicanna

Avicanna Inc., a commercial-stage and international biopharmaceutical company, focuses on the development, advancement, and commercialization of evidence-based cannabinoid-based products for worldwide consumers and for medical and pharmaceutical market segments. The company collaborates with Canadian academic and medical institutions. Its scientific platform includes advanced research and development, and clinical development that leads to the commercialization of approximately twenty products across four main market segments. The company provides medical and wellness products, such as oral, sublingual, topical, and transdermal deliveries under the RHO Phyto brand; functional CBD consumer derma-cosmetic and topical products under the Pura H&W and Pura Earth brand names; and feminized and standardized seeds, resins or whole plant crude oils, cannabinoid distillates, and isolated cannabinoids and bulk formulations under the Aureus brand. It also offers cannabidiol, cannabigerol, and tetrahydrocannabinol seeds under the Avesta Genetica brand name. In addition, the company is developing pharmaceutical products for epidermolysis bullosa, eczema, acne, anxiety and depression, sleep disorders, opioid addiction, epilepsy, Parkinson's disease, multiple sclerosis, chronic pain, neuropathic pain, arthritis, and palliative care diseases. Avicanna has research collaboration with Dr. Christine Allen'sResearch Group for the development of a cannabinoid-based treatment for lung inflammation associated with COVID19. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.
Read More

Today's Range

Now: $0.31
Low: $0.29
High: $0.31

50 Day Range

MA: $0.26
Low: $0.20
High: $0.31

52 Week Range

Now: $0.31
Low: $0.17
High: $1.24

Volume

7,240 shs

Average Volume

12,759 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Avicanna?

The following Wall Street research analysts have issued stock ratings on Avicanna in the last year: Raymond James.
View the latest analyst ratings for AVCNF.

What is the current price target for Avicanna?

0 Wall Street analysts have set twelve-month price targets for Avicanna in the last year.
View the latest price targets for AVCNF.

What is the current consensus analyst rating for Avicanna?

Avicanna currently has 1 sell rating from Wall Street analysts. The stock has a consensus analyst rating of "Sell." A "sell" rating indicates that analysts believe AVCNF will underperform the market and that investors should sell shares of Avicanna.
View the latest ratings for AVCNF.

How do I contact Avicanna's investor relations team?

Avicanna's physical mailing address is 480 University Avenue, Toronto, ON M5G. The company's listed phone number is 1.647.243.5283. The official website for Avicanna is www.avicanna.com. Learn More about contacing Avicanna investor relations.